Plasmapheresis as a therapeutic measure in hemolytic-uremic syndrome in children.
Three children with hemolytic-uremic syndrome (HUS) were successfully treated with plasmapheresis (HUS) were successfully treated with plasmapheresis (PP) combined with early hemodialysis and administration of Aspirin and dipyridamole. Stimulation of vascular prostacyclin release with patients' plasma was measured before and after PP. It was reduced before and increased after plasma exchange. The data indicate that PP might be a useful tool in treatment of (HUS) in children.
D001241:Aspirin / Q000627:therapeutic use; D002675:Child, Preschool; D004176:Dipyridamole / Q000627:therapeutic use; D011464:Epoprostenol / Q000097:blood; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D007223:Infant; D008297:Male; D010956:Plasmapheresis; D006435:Renal Dialysis
D004176:Dipyridamole; D011464:Epoprostenol; D001241:Aspirin